You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

ACTIMMUNE Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Recent Clinical Trials for ACTIMMUNE

Identify potential brand extensions & biosimilar entrants

SponsorPhase
University of Colorado, DenverPhase 1
IRCCS Eugenio MedeaPhase 2
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterPhase 2

See all ACTIMMUNE clinical trials

Recent Litigation for ACTIMMUNE

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
AMGEN INC. v. APOTEX INC.2022-06-14
Celgene Corporation v. Aurobindo Pharma Limited2018-07-06
AMGEN INC. v. EMCURE PHARMACEUTICALS LTD.2018-06-28

See all ACTIMMUNE litigation

Pharmacology for ACTIMMUNE
Established Pharmacologic ClassInterferon gamma
Chemical StructureInterferon-gamma
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ACTIMMUNE Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ACTIMMUNE Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ACTIMMUNE Derived from Patent Text Search

These patents were obtained by searching patent claims
Showing 1 to 7 of 7 entries

Market Dynamics and Financial Trajectory for the Biologic Drug: ACTIMMUNE

Introduction

ACTIMMUNE®, a biologically manufactured protein, is used to treat Chronic Granulomatous Disease (CGD), a genetic disorder that increases the risk of serious infections. To understand the market dynamics and financial trajectory of ACTIMMUNE, we need to delve into several key areas, including the broader biologics market, the performance of its parent company, and specific product metrics.

The Broader Biologics Market

The biologic therapeutic drugs market is experiencing significant growth. According to recent research, this market is expected to grow from $452.9 billion in 2023 to $823.4 billion by 2028, with a compound annual growth rate (CAGR) of 12.7% during the forecast period[3].

Key Drivers of the Biologics Market

  • Increasing Demand for Therapeutic Proteins: The demand for biologic therapeutic drugs, including those for rare and chronic diseases, is on the rise.
  • Advancements in Cell and Gene Therapy: Modern biologic manufacturing, including cell and gene therapy, is driving innovation and growth in the sector.
  • Regulatory Support: Favorable regulatory environments, especially in regions like North America and Europe, are facilitating the development and approval of new biologics[3].

Performance of Amgen and Horizon Therapeutics

ACTIMMUNE is part of the portfolio acquired by Amgen through its acquisition of Horizon Therapeutics. Here’s a look at how Amgen’s financial performance and product sales can provide context for ACTIMMUNE.

Amgen's Financial Performance

In the third quarter of 2024, Amgen reported strong financial results, with total revenues increasing by 23% to $8.5 billion. Product sales grew by 24%, driven by a 29% volume growth, partially offset by a 2% lower net selling price. This growth includes contributions from various products, including those acquired from Horizon Therapeutics[2].

Product Sales and Revenue Growth

Amgen's product sales have seen significant growth, with ten products achieving double-digit sales growth in the third quarter of 2024. While ACTIMMUNE is not specifically highlighted among these top performers, the overall growth trend suggests a positive environment for biologic drugs within Amgen's portfolio[2].

ACTIMMUNE Specifics

Clinical Impact and Market Position

ACTIMMUNE has been proven to reduce serious infections in patients with CGD. In clinical studies, it has shown a 64% lower risk of serious infections and a 67% decrease in days spent in the hospital[4].

Market Segmentation

ACTIMMUNE falls under the rare disease segment, which is a growing area within the biologics market. Amgen reported $1.2 billion in rare disease product sales in the third quarter of 2024, indicating a strong market presence in this niche[2].

Financial Support and Access

To enhance patient access, ACTIMMUNE offers financial support programs, including co-pay assistance and other resources, which can help in maintaining and growing its market share[5].

Financial Trajectory

Revenue Contribution

While specific revenue figures for ACTIMMUNE are not provided in the latest financial reports, the product is part of the broader rare disease portfolio that has seen significant growth. Given the overall performance of Amgen's rare disease segment, it is reasonable to infer that ACTIMMUNE contributes positively to these revenues.

Growth Prospects

The acquisition by Amgen and the integration into a larger portfolio with significant resources are likely to enhance ACTIMMUNE's market reach and growth prospects. The strong financial performance of Amgen and the growing demand for biologic therapeutic drugs suggest a favorable financial trajectory for ACTIMMUNE.

Competitive Landscape

Market Players

The biologics market is highly competitive, with several major players. However, ACTIMMUNE's niche in treating CGD positions it uniquely in the market. The support from Amgen, a leading biotechnology company, further strengthens its competitive stance[3].

Regulatory and Market Trends

Regulatory Environment

The regulatory environment continues to support the development and approval of biologic drugs. This favorable environment is crucial for the continued growth of ACTIMMUNE and other biologics in the market[3].

Market Trends

The trend towards personalized and targeted therapies is driving the demand for biologic drugs. ACTIMMUNE, being a biologically manufactured protein, aligns well with these trends and is likely to benefit from the increasing adoption of such therapies.

Key Takeaways

  • Growing Biologics Market: The biologic therapeutic drugs market is expected to grow significantly, driven by increasing demand and advancements in technology.
  • Strong Financial Performance: Amgen's financial results indicate a strong environment for biologic drugs, including those acquired from Horizon Therapeutics.
  • Clinical Impact: ACTIMMUNE has a proven clinical impact in reducing serious infections in CGD patients.
  • Financial Support: The product benefits from financial support programs, enhancing patient access.
  • Growth Prospects: The integration into Amgen's portfolio and the growing demand for biologics suggest a positive financial trajectory for ACTIMMUNE.

FAQs

What is ACTIMMUNE used for?

ACTIMMUNE is used to treat Chronic Granulomatous Disease (CGD), a genetic disorder that increases the risk of serious infections.

How does ACTIMMUNE reduce infections in CGD patients?

ACTIMMUNE has been shown to reduce serious infections by 64% and decrease hospital days by 67% in clinical studies.

Who acquired ACTIMMUNE?

ACTIMMUNE was acquired by Amgen as part of its acquisition of Horizon Therapeutics.

What is the expected growth rate of the biologics market?

The biologic therapeutic drugs market is expected to grow at a CAGR of 12.7% from 2023 to 2028.

How does Amgen support patient access to ACTIMMUNE?

Amgen offers financial support programs, including co-pay assistance, to enhance patient access to ACTIMMUNE.

Sources

  1. AMGEN Reports Fourth Quarter and Full Year 2023 Financial Results - AMGEN Press Release[1].
  2. AMGEN Reports Third Quarter 2024 Financial Results - Stock Titan[2].
  3. Big Growth Ahead Biologic Drugs Market to Hit 823.4 Billion by 2028 - BCC Research[3].
  4. ACTIMMUNE Brochure - ACTIMMUNE Official Website[4].
  5. Your Support Team | ACTIMMUNE - ACTIMMUNE Official Website[5].

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.